The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression.
Paula Rodríguez-Otero, MD, PhD
Advertisement
Articles by Paula Rodríguez-Otero, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Survey Reveals Clinician Confidence Around Using AI in PA Process
3
How Medicaid Reforms Could Deepen State Coverage Gaps
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5
